This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n15http://linked.opendata.cz/ontology/domain/vavai/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00669806%3A_____%2F13%3A10193077%21RIV14-MZ0-00669806/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00669806%3A_____%2F13%3A10193077%21RIV14-MZ0-00669806
rdf:type
skos:Concept n15:Vysledek
dcterms:description
A multiplex panel for the measurement of serum levels, including osteoprotegerin, osteopontin, osteocalcin, parathormon and leptin, was tested in a group of cancer patients with metastatic disease, and also in healthy controls. Methods: Cancer cases were divided into one group with an occurrence of bone metastases and into one group without bone metastases. Serum levels of markers of biologic activity were measured using Human Bone Panel for multiplex xMAP technology. Additionaly, routine serum bone markers (PINP, PIIINP, ostase, ICTP and 25-hydroxyvitamin D) were assessed with routine immunoassays in cancer groups. Results:In comparison to controls, both cancer groups were observed to have higher levels of osteoprotegerin and lower levels of osteocalcin. The bone metastatic group had higher levels of PIIINP and ostase than the non-bonemetastatic group. 3 of 4 patients with multiple bone metastases had values above the set normal value for both osteoprotegerin and osteopontin in comparison to all other cancer patients. Conclusions: Multiplex bone metastasis detection by serum test in future could help with creating of multiparametric scoring system with sufficient sensitivity and specificity for clinical practise. Multiplex is a powerful tool for multiparametric studies, but we are still in the era of looking for the right marker combinations for cancer diagnostics and monitoring. The panel will be tested on a larger cancer cohort and in patients with non-cancerous diseases. A multiplex panel for the measurement of serum levels, including osteoprotegerin, osteopontin, osteocalcin, parathormon and leptin, was tested in a group of cancer patients with metastatic disease, and also in healthy controls. Methods: Cancer cases were divided into one group with an occurrence of bone metastases and into one group without bone metastases. Serum levels of markers of biologic activity were measured using Human Bone Panel for multiplex xMAP technology. Additionaly, routine serum bone markers (PINP, PIIINP, ostase, ICTP and 25-hydroxyvitamin D) were assessed with routine immunoassays in cancer groups. Results:In comparison to controls, both cancer groups were observed to have higher levels of osteoprotegerin and lower levels of osteocalcin. The bone metastatic group had higher levels of PIIINP and ostase than the non-bonemetastatic group. 3 of 4 patients with multiple bone metastases had values above the set normal value for both osteoprotegerin and osteopontin in comparison to all other cancer patients. Conclusions: Multiplex bone metastasis detection by serum test in future could help with creating of multiparametric scoring system with sufficient sensitivity and specificity for clinical practise. Multiplex is a powerful tool for multiparametric studies, but we are still in the era of looking for the right marker combinations for cancer diagnostics and monitoring. The panel will be tested on a larger cancer cohort and in patients with non-cancerous diseases.
dcterms:title
Markers of metastatic bone process - test of multiplex assay Markers of metastatic bone process - test of multiplex assay
skos:prefLabel
Markers of metastatic bone process - test of multiplex assay Markers of metastatic bone process - test of multiplex assay
skos:notation
RIV/00669806:_____/13:10193077!RIV14-MZ0-00669806
n15:predkladatel
n18:ico%3A00669806
n3:aktivita
n8:P n8:I
n3:aktivity
I, P(NT13655)
n3:cisloPeriodika
79
n3:dodaniDat
n14:2014
n3:domaciTvurceVysledku
n7:4256603 n7:7725825 n7:9221670 n7:8219303
n3:druhVysledku
n9:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
86395
n3:idVysledku
RIV/00669806:_____/13:10193077
n3:jazykVysledku
n16:eng
n3:klicovaSlova
panel; biologic activity markers; multiplex; Metastatic disease
n3:klicoveSlovo
n4:Metastatic%20disease n4:panel n4:biologic%20activity%20markers n4:multiplex
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[A1E6DFF5D998]
n3:nazevZdroje
Plzeňský lékařský sborník
n3:obor
n11:FD
n3:pocetDomacichTvurcuVysledku
4
n3:pocetTvurcuVysledku
5
n3:projekt
n17:NT13655
n3:rokUplatneniVysledku
n14:2013
n3:svazekPeriodika
2013
n3:tvurceVysledku
Topolčan, Ondřej Pražáková, Markéta Vrzalová, Jindra Fínek, Jindřich Fuchsová, Radka
s:issn
0551-1038
s:numberOfPages
10